Clinical Review

Atypical Features of COVID-19: A Literature Review


 

References

Conclusion

Evidence regarding atypical features of COVID-19 is accumulating. SARS-CoV-2 can infect a human cells that express the ACE2 receptor, which would allow for a broad spectrum of illnesses. The potential for SARS-CoV-2 to induce a hypercoagulable state allows it to indirectly damage various organ systems,20 leading to cerebrovascular disease, myocardial injury, and a chilblain-like rash. Clinicians must be aware of these unique features, as early recognition of persons who present with COVID-19 will allow for prompt testing, institution of infection control and isolation practices, and treatment, as needed, among those infected. Also, this is a pandemic involving a novel virus affecting different populations throughout the world, and these signs and symptoms may occur with varying frequency across populations. Therefore, it is important to keep differentials broad when assessing patients with a clinical illness that may indeed be COVID-19.

Corresponding author: Norman L. Beatty, MD, norman.beatty@medicine.ufl.edu.

Financial disclosures: None.

Pages

Recommended Reading

Consider COVID-19–associated multisystem hyperinflammatory syndrome
Journal of Clinical Outcomes Management
Hazard pay included in new COVID-19 relief bill
Journal of Clinical Outcomes Management
Dermatologic changes with COVID-19: What we know and don’t know
Journal of Clinical Outcomes Management
COVID-19 in kids: Severe illness most common in infants, teens
Journal of Clinical Outcomes Management
Antibody testing suggests COVID-19 cases are being missed
Journal of Clinical Outcomes Management
Vitamin D: A low-hanging fruit in COVID-19?
Journal of Clinical Outcomes Management
Maskomania: Masks and COVID-19
Journal of Clinical Outcomes Management
Inflammation, thrombosis biomarkers tied to COVID-19 deaths
Journal of Clinical Outcomes Management
Today’s top news highlights: Risks & benefits of universal masking, prostate cancer rising
Journal of Clinical Outcomes Management
Remdesivir in Hospitalized Adults With Severe COVID-19: Lessons Learned From the First Randomized Trial
Journal of Clinical Outcomes Management